{"meshTags":["Male","Acid Phosphatase","Antigen-Antibody Complex","Radioimmunoassay","Antibodies, Monoclonal","Neoplasm Proteins","Enzyme-Linked Immunosorbent Assay","Prostatic Neoplasms","Humans","Antigens, Neoplasm","Counterimmunoelectrophoresis","Fluorescent Antibody Technique","Prostate-Specific Antigen","Immunosorbent Techniques","Prostate"],"meshMinor":["Male","Acid Phosphatase","Antigen-Antibody Complex","Radioimmunoassay","Antibodies, Monoclonal","Neoplasm Proteins","Enzyme-Linked Immunosorbent Assay","Prostatic Neoplasms","Humans","Antigens, Neoplasm","Counterimmunoelectrophoresis","Fluorescent Antibody Technique","Prostate-Specific Antigen","Immunosorbent Techniques","Prostate"],"genes":["prostatic acid phosphatase","prostate-specific antigen","Prostatic acid phosphatase","prostatic antigen"],"organisms":["9606"],"publicationTypes":["Journal Article","Research Support, Non-U.S. Gov\u0027t","Review"],"abstract":"The authors review recent developments in the immunodiagnosis of prostatic cancer. Monoclonal antibodies to prostatic acid phosphatase, prostate-specific antigen, and several human prostate and prostate-cancer-related components are available. Prostatic acid phosphatase and prostatic antigen assays are still the only immunologic tools with clinical applications.","title":"Immunologic markers and the diagnosis of prostatic cancer.","pubmedId":"6203206"}